Geneva, May 29 -- International Clinical Trials Registry received information related to the study (ChiCTR2600125048) titled 'Clinical Study on the Safety and Efficacy of Gicitinib Hydrochloride Tablets Combined with Standard Immunotherapy in the First-Line Treatment of Chronic Graft-Versus-Host Disease' on May 20.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The First Affiliated Hospital of Zhengzhou University

Condition: Chronic Graft-Versus-Host Disease

Recruitment Status: Recruiting

Phase: 4

Date of First Enrollment: 2026-05-08

Target Sample Size: Experimental Group:10;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=315270

Published by HT ...